Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 14/20 | 0.64 |
| ▸ | PTGIR | P43119 | 1/20 | 0.50 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.47 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.45 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13063072 | 0.84 | WDR5 (0.55) | WDR5PTGIR | |
| SCHEMBL10054979 | 0.80 | PTGIR (0.69) | WDR5PTGIRCXCR4APOBEC3AAPOBEC3G | |
| SCHEMBL6666934 | 0.80 | WDR5 (0.71) | WDR5PTGIRCXCR4 | |
| SCHEMBL21711684 | 0.80 | WDR5 (1.00) | WDR5 | |
| SCHEMBL4035161 | 0.77 | PTGIR (0.61) | WDR5PTGIRCXCR4APOBEC3AAPOBEC3G | |
| SCHEMBL3169468 | 0.76 | PTGIR (0.60) | WDR5PTGIRCXCR4APOBEC3AAPOBEC3G | |
| SCHEMBL12139511 | 0.75 | WDR5 (0.47) | WDR5APOBEC3AAPOBEC3GADRA2AADRA2B | |
| SCHEMBL21711636 | 0.75 | WDR5 (1.00) | WDR5 | |
| SCHEMBL21711558 | 0.75 | WDR5 (1.00) | WDR5 | |
| SCHEMBL4032956 | 0.75 | PTGIR (0.62) | WDR5PTGIRCXCR4APOBEC3AAPOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1296958-A4 | IMINOPYRIMIDINE NMDA NR2B RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002000629-A9 | IMINOPYRIMIDINE NMDA NR2B RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2003-05-15 | — | — | WO | disclosed |
| EP-1296958-A1 | IMINOPYRIMIDINE NMDA NR2B RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| US-6440976-B2 | FOR THERAPY OF PAIN, MIGRAINE, DEPRESSION, ANXIETY, SCHIZOPHRENIA, PARKINSON'S DISEASE, STROKE, AND IN THERAPY OF NEUROPATHIES INCLUDING POSTHERPETIC NEURALGIA, CENTRAL PAIN FROM SPINAL CORD INJURY, AND PHANTOM LIMB PAIN | MERCK & CO., INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020013329-A1 | Iminopyrimidine NMDA NR2B receptor antagonists | MERCK & CO., INC. | 2002-01-31 | — | — | US | disclosed |
| WO-2002000629-A1 | IMINOPYRIMIDINE NMDA NR2B RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013329-A1 | Iminopyrimidine NMDA NR2B receptor antagonists | GRIN1, GRIN2B, GRIN2C | WDR5 2268/4885PTGIR 887/4885CXCR4 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.